Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of ($1.17), $0.09 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $50.8 million versus the consensus estimate of $45.67 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.